Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26346667 | 1.00 | MEN1 (0.47) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL25457850 | 0.98 | MAPK1 (0.44) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL19309079 | 0.89 | MEN1 (0.56) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL5155263 | 0.89 | MEN1 (0.56) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL5157716 | 0.87 | MAPK1 (0.55) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL19155984 | 0.86 | MEN1 (0.43) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL18532464 | 0.86 | ADRA1A (0.52) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL24490705 | 0.86 | ADRA1A (0.52) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL22690587 | 0.86 | ADRA1A (0.52) | MEN1KMT2AMAPK1KDM4EHIF1A | |
| SCHEMBL13056634 | 0.86 | ADRA1A (0.52) | MEN1KMT2AMAPK1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20170254798-A1 | METHOD FOR SCREENING DRUG-SACCHARIDE CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170248580-A1 | METHOD FOR SCREENING DRUG-SACCHARIDE CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | MEN1 886/4885KMT2A 3498/4885MAPK1 2798/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | MEN1 342/4885KMT2A 2821/4885MAPK1 1090/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | MEN1 279/4885KMT2A 2558/4885MAPK1 1013/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | MEN1 2203/4885KMT2A 2729/4885MAPK1 3878/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | MEN1 342/4885KMT2A 2821/4885MAPK1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.